Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.

Inclusion Criteria:

Physician inclusion criteria

• The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
• The physician has cared for at least ten nmHSPC patients in the past year.
• The physician has experience prescribing NHT and ADT. Patient inclusion criteria
• The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.

Exclusion Criteria:

Physician exclusion criteria

• None Patient exclusion criteria
• The patient is castration resistant.
• The patient has metastatic PC.